<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993639</url>
  </required_header>
  <id_info>
    <org_study_id>125-101</org_study_id>
    <nct_id>NCT03993639</nct_id>
  </id_info>
  <brief_title>KRN125 for Mobilization of Hematopoietic Stem Cells</brief_title>
  <official_title>A Phase II Clinical Trial of KRN125 to Mobilize Hematopoietic Stem Cells Into Peripheral Blood in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into
      the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy
      adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KRN125 is administered as a single SC dose to the Day 1. The stem cell mobilization protocols
      will be monitored for safety and efficacy during the mobilization period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase II, single center, open label, non-control, dose setting study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achievement of &gt;20 cells/μL positive for CD34 in peripheral blood from baseline to Day 7</measure>
    <time_frame>Baseline to Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Period from baseline to first time peripheral blood CD34 positive cells &gt;20 cells/μL</measure>
    <time_frame>Baseline to Day 15 or through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Time from baseline to peak peripheral blood CD34 positive cells</measure>
    <time_frame>Baseline to Day 15 or through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Achievement of &gt;10 cells/μL positive for CD34 in peripheral blood from baseline to Day 7</measure>
    <time_frame>Baseline to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Peripheral blood CD34 positive cell count</measure>
    <time_frame>Baseline to Day 15 or through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Peripheral blood white blood cell count</measure>
    <time_frame>Baseline to Day 15 or through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Peripheral blood neutrophil count</measure>
    <time_frame>Baseline to Day 15 or through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Peripheral Blood Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>KRN125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single SC administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegfilgrastim</intervention_name>
    <description>Single dose of SC administration</description>
    <arm_group_label>KRN125</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese subjects aged 20 to 55 years or younger at the submission of the written
             informed consent form

          -  Women weighing 40 kg or more and 80 kg or less and men weighing 45 kg or more and 80
             kg or less at the time of the preliminary examination

        Exclusion Criteria:

          -  Subjects with a current medical history or who have been judged to be inappropriate
             for the study (e.g., significant neurological, hepatic, renal, endocrine,
             cardiovascular, blood, gastrointestinal, respiratory, and metabolic diseases,
             malignancies, myeloproliferative disorder, or psychiatric disorders)

          -  Individuals with alcohol or drug dependence, or individuals who have not tested
             negative for all drugs of abuse in the preliminary test

          -  Subjects with a history or current history of drug allergy or symptomatic allergy

          -  .Active infection or history of recurrent infection- However, only patients who are
             HBsantibody-positive by hepatitis B vaccination and whose HBV-DNA is less than the
             lower limit of quantitation will be allowed to participate in this study.

          -  Subjects who used drugs within 2 weeks before administration of the investigational
             drug.

          -  Subjects who have had at least 200 mL of blood drawn within 3 months before
             administration of the investigational drug.

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Kirin Co., Ltd.</last_name>
    <phone>+81-3-5205-7200</phone>
    <email>clinical.info.jp@kyowakirin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+81-11-706-7061</phone>
      <email>tiken@med.hokudai.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic Stem Cells Mobilization</keyword>
  <keyword>Healthy Volunteer (HV)</keyword>
  <keyword>filgrastim</keyword>
  <keyword>allogenic hematopoetic stem cell transplantation</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

